Screw the promo and hype , I will settle for results.Make no mistake about it BCT has put together a dream team and although they may be lagging in the promo of their stock department these guys have the ability to make something very special happen. If you are looking for a quick trade type stock I would say skip it. If you are looking to put a few thousand dollars into that could change your financial situation in a HUGE way this is the group to put your money on.
When you look at the team that is assembled here and the fact that early trials have gone so well this may well be the most undervalued pharma play on any market in North America . Just read the creds of Dr O'Day and he is just support staff.....I like my BCT position and after looking at some of this info again can not believe I have not added to it lately. That will change on Monday.
BriaCell Therapeutics Announces Top US Oncologist to Lead Its Clinical Trial
Dr. Steven O'Day as Principal Investigator for Upcoming Phase I/II Clinical Trial
VANCOUVER, BC--(Marketwired - January 07, 2015) - BriaCell Therapeutics Corp (TSX VENTURE: BCT) ("BriaCell", the "Company", or "BCT") is pleased to announce that it has formally engaged Dr. Steven J. O'Day as Principal Investigator for the Company's upcoming BriaVax™ vaccine clinical trial. Dr. O'Day is a highly specialized oncologist with a history of leading successful clinical trials, having been educated and trained at Johns Hopkins, Harvard, and Oxford.
As BriaCell's Principal Investigator, Dr. O'Day brings a track record of experience as the Principal Investigator on over 100 clinical trials including several large, international Phase III clinical trials. Dr. O'Day served as the Principal Investigator in Bristol-Myers Squibb's Phase III clinical trial for its Yervoy, widely heralded as a scientific breakthrough. The renowned clinical trial, which included 676 patients, saw a significant improvement in overall survival for late-stage melanoma patients. Yervoy became the first and only drug ever to extend survival in patients with advanced forms of melanoma. Yervoy has rapidly become the highest grossing melanoma drug in the US and major EU markets. In 2012, Yervoy sales were over $700m, and are forecasted to be $1b per year by 2018.
Dr. Charles L. Wiseman, BriaCell's Chief Medical Officer commented, "Dr. O'Day is known as the very best of the best, and for those in the scientific community, he needs no introduction. I have always felt strongly regarding the importance of having a top caliber team. We may still be an early stage company, but I believe we are building a highly specialized team capable of advancing our promising vaccine as effectively as possible. We are thrilled to have Dr. O'Day on board."
Dr. O'Day is recognized as one of the preeminent cancer specialists in the world, and combines expert clinical care with teaching and leading clinical research. He lectures extensively, both nationally and internationally. His research has focused for many years on the combination of chemotherapy and immunotherapy in the treatment of metastatic cancers. He has been at the forefront of new drug development in over the last two decades. He has published more than 200 manuscripts, abstracts and reviews in prestigious journals such as The New England Journal of Medicine, Journal of Clinical Oncology, Blood, Journal of American Medical Association, Lancet Oncology and the Journal of the National Cancer Institute. He serves on the editorial boards and as a reviewer for many prestigious journals including JCO and Clinical Cancer Research. Dr. O'Day has served on the ASCO Education Committee for melanoma. In addition, he has served on the ASCO International Development and Education Award (IDEA) Working Group where he has served as a mentor for an IDEA grant recipient as well as an IDEA grant reviewer.
Dr. O'Day has regularly been interviewed and cited by the media, and was recently quoted in a Bloomberg article on immunotherapies. Dr. O'Day attended medical school at Johns Hopkins University and subsequently completed his fellowship in Medical Oncology at Harvard University. Dr. O'Day also studied Medical Ethics at Oxford University.